MDT insider ownership: who sold, why, and what they still hold

Who	Shares	Price	% of total stake	Total stake after	Trade date	Filed
Harry Kiil EVP & President Cardiovascular	1,483	$93.65	3.5%	41K	Sep 16, 2026	Sep 17, 2026

Who	Shares	Price	% of total stake	Total stake after	Trade date	Filed
Denise Blomquist Chief Accounting Officer	600	n/a	3.6%	16K	Sep 15, 2026	Sep 16, 2026

What stands out

Gregory Smith sold 40% of vested holdings: 30K shares for $3.1M, none under a disclosed plan.Largest sale, Nov 19, 2025

Harry Kiil sold $5.6M of stock with no disclosed trading plan. The filings don't state a reason.Largest such sale, Feb 19, 2026

Matthew Walter sold 3.1K shares (9.7% of starting holdings), but 16K more vested, so the stake grew (from 32K to 40K).Largest sale, Jul 8, 2026

Percentages cover 19 of 22 officers and directors. Left out: Harry Kiil (most of their shares vested during the period, so a percentage would mislead); Joon Lee and John Groetelaars (held no vested shares at the start). Disclosed company stock is not an insider's whole wealth.

Who sold, and how much of their stake

Officers and directors, past 12 months. Each bar is the insider's vested stake at the start of the period (Oct 8, 2025). The gold part is what they sold.

SoldRest of starting stakeAdded during the period

Harry Kiil

EVP & President Cardiovascular

Sold 59% of the shares held or received (after tax withholding) during the period†. No bar against the starting stake: most of these shares arrived during the period.

$5.6MNo plan disclosed

Gregory Smith

EVP Global Ops & Supply Chain

40% · $3.1MNo plan disclosed

Matthew Walter

SVP, Chief HR Officer

Sold 9.7%, but 9.1K shares were added (mostly vesting), so the stake grew

9.7% · $258KDisclosed plan

Amounts, filings and trading plans for each seller

Selling by month

Officers and directors, Oct 2025 to Oct 2026. Each sale is counted once: under a disclosed plan, else to cover taxes, else no plan disclosed.

Disclosed planTo cover taxesNo plan disclosed

Common questions

Is the Medtronic CEO selling stock?

No. Geoffrey Martha reported no open-market sales in the past 12 months.

Why are Medtronic insiders selling?

Filings rarely give a reason, and we don't guess at one. What they show is how the sales were made: 3% of sales by value ran under 10b5-1 trading plans disclosed in the filings and 97% had no disclosed plan. A trading plan schedules sales in advance.

Are any Medtronic insiders buying?

No. Officers and directors reported no purchases in the past 12 months.

How much of their stake did Medtronic insiders sell?

About 4.3% overall. As a group they ended with more shares than they started with. The biggest seller whose stake can be measured, Gregory Smith, gave up 40% of starting holdings. That covers the 12 months to Oct 8, 2026 and counts vested shares reported on SEC Forms 3, 4 and 5, which is not an insider's whole wealth.

The evidence

Who sold3 officers and directors: amount, % of holdings, trading plan

Who sold	Amount	% of holdings	Trading plan
Harry Kiil EVP & President Cardiovascular	$5.6M 58K shares	59%† i † Most of the shares Harry Kiil sold arrived during the period, so this is shares sold as a share of the 36K held at the start plus the 75K received, less 12K withheld by the company for taxes.	No plan disclosed
Gregory Smith EVP Global Ops & Supply Chain	$3.1M 30K shares	40%	No plan disclosed
Matthew Walter SVP, Chief HR Officer	$258K 3.1K shares	9.7%	Disclosed plan

The full ownership picture22 of 22 insiders fully reconciled · 22 officers and directors

Vested shares across all share classes, held directly and through trusts, LLCs and family members, as reported on SEC Forms 3, 4 and 5. Unvested awards and options are never counted as owned shares.

Insider

Held Oct 8, 2025

Sold

Held Oct 8, 2026

Still held

Geoffrey Martha

Minor difference of 3,555 shares. Difference is stated in footnotes (unreported vesting, exempt acquisition or transfer). Includes unvested RSUs, amount not disclosed.

Chairman and CEO, Director

247K

328K

no sales

Vesting, gifts, unvested awards and holding lines for Geoffrey Martha

+95Kshares vested or exercised

0gifted (net of own trusts)

−59Kwithheld by the company for taxes

194K → 298Kunvested awards, start → end

Includes unvested RSUs, amount not disclosed.

Held through	Share class	Oct 8, 2025	Oct 8, 2026
Direct includes unvested RSUs, amount not disclosed	Ordinary Shares	247,125	327,866

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
295,680	$80.00	Jul 29, 2034	$4.0M
264,518	$91.97	Jul 28, 2035	$444K
295,002	$86.68	Aug 3, 2036	$2.1M
273,150	$86.68	Aug 3, 2036	$1.9M

Estimate: options held × ($93.65 − strike price), using the most recent insider trade price on Form 4 (Sep 16, 2026), not a market close.

Reconciliation: minor difference of 3,555 shares. Difference is stated in footnotes (unreported vesting, exempt acquisition or transfer).

Gregory Smith

Minor difference of 59 shares. Difference is under 0.5% of holdings. Includes unvested RSUs, amount not disclosed.

EVP Global Ops & Supply Chain

76K

−30K

46K

61%

Vesting, gifts, unvested awards and holding lines for Gregory Smith

0shares vested or exercised

0gifted (net of own trusts)

60K → 60Kunvested awards, start → end

Includes unvested RSUs, amount not disclosed.

Held through	Share class	Oct 8, 2025	Oct 8, 2026
Direct includes unvested RSUs, amount not disclosed	Ordinary Shares	75,957	46,016

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
106,260	$80.00	Jul 29, 2034	$1.5M
69,005	$91.97	Jul 28, 2035	$116K

Estimate: options held × ($93.65 − strike price), using the most recent insider trade price on Form 4 (Sep 16, 2026), not a market close.

Reconciliation: minor difference of 59 shares. Difference is under 0.5% of holdings.

Brett Wall

Minor difference of 778 shares. Difference is stated in footnotes (unreported vesting, exempt acquisition or transfer). Includes unvested RSUs, amount not disclosed.

EVP & Pres Neuroscience

55K

82K

no sales

Vesting, gifts, unvested awards and holding lines for Brett Wall

+27Kshares vested or exercised

0gifted (net of own trusts)

−439withheld by the company for taxes

60K → 60Kunvested awards, start → end

Includes unvested RSUs, amount not disclosed.

Held through	Share class	Oct 8, 2025	Oct 8, 2026
Direct includes unvested RSUs, amount not disclosed	Ordinary Shares	54,937	82,183

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
106,260	$80.00	Jul 29, 2034	$1.5M
69,005	$91.97	Jul 28, 2035	$116K

Estimate: options held × ($93.65 − strike price), using the most recent insider trade price on Form 4 (Sep 16, 2026), not a market close.

Reconciliation: minor difference of 778 shares. Difference is stated in footnotes (unreported vesting, exempt acquisition or transfer).

Michael Marinaro

Minor difference of 1,578 shares. Difference is stated in footnotes (unreported vesting, exempt acquisition or transfer). Includes unvested RSUs, amount not disclosed.

EVP, Pres MedSurg and Americas

52K

116K

no sales

Vesting, gifts, unvested awards and holding lines for Michael Marinaro

+19Kshares vested or exercised

0gifted (net of own trusts)

−13Kwithheld by the company for taxes

59K → 86Kunvested awards, start → end

Includes unvested RSUs, amount not disclosed.

Held through	Share class	Oct 8, 2025	Oct 8, 2026
Direct includes unvested RSUs, amount not disclosed	Ordinary Shares	51,939	116,336

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
101,640	$80.00	Jul 29, 2034	$1.4M
69,005	$91.97	Jul 28, 2035	$116K
77,848	$86.68	Aug 3, 2036	$543K

Estimate: options held × ($93.65 − strike price), using the most recent insider trade price on Form 4 (Sep 16, 2026), not a market close.

Reconciliation: minor difference of 1,578 shares. Difference is stated in footnotes (unreported vesting, exempt acquisition or transfer).

Kendall Powell

Minor difference of 854 shares. Difference is stated in footnotes (unreported vesting, exempt acquisition or transfer). Includes unvested RSUs, amount not disclosed. Additional holdings last reported more than 3 years ago are shown separately and excluded from totals.

Director

49K

51K

no sales

Vesting, gifts, unvested awards and holding lines for Kendall Powell

0shares vested or exercised

0gifted (net of own trusts)

−207withheld by the company for taxes

none reportedunvested awards, start → end

Includes unvested RSUs, amount not disclosed.
Additional holdings last reported more than 3 years ago are shown separately and excluded from totals.

Held through	Share class	Oct 8, 2025	Oct 8, 2026
Direct includes unvested RSUs, amount not disclosed	Ordinary Shares	48,622	51,380

Additional holdings last reported May 2, 2023, not confirmed since: 3,000 shares. Not included in any total or percentage on this page.

Spouse Revocable Trust, Ordinary Shares: 3,000 shares, last reported May 2, 2023

Reconciliation: minor difference of 854 shares. Difference is stated in footnotes (unreported vesting, exempt acquisition or transfer).

Randall Hogan

Minor difference of 65 shares. Difference is stated in footnotes (unreported vesting, exempt acquisition or transfer). Includes unvested RSUs, amount not disclosed. Additional holdings last reported more than 3 years ago are shown separately and excluded from totals.

Director

47K

49K

no sales

Vesting, gifts, unvested awards and holding lines for Randall Hogan

0shares vested or exercised

0gifted (net of own trusts)

−207withheld by the company for taxes

none reportedunvested awards, start → end

Includes unvested RSUs, amount not disclosed.
Additional holdings last reported more than 3 years ago are shown separately and excluded from totals.

Held through	Share class	Oct 8, 2025	Oct 8, 2026
Direct includes unvested RSUs, amount not disclosed	Ordinary Shares	47,029	48,998

Additional holdings last reported May 2, 2023, not confirmed since: 37,145 shares. Not included in any total or percentage on this page.

Family Limited Partnership, Ordinary Shares: 36,798 shares, last reported May 2, 2023
Ira, Ordinary Shares: 286 shares, last reported May 2, 2023
Trust, Ordinary Shares: 61 shares, last reported Apr 27, 2015

Reconciliation: minor difference of 65 shares. Difference is stated in footnotes (unreported vesting, exempt acquisition or transfer).

Craig Arnold

Minor difference of 65 shares. Difference is stated in footnotes (unreported vesting, exempt acquisition or transfer). Includes unvested RSUs, amount not disclosed.

Director

40K

42K

no sales

Vesting, gifts, unvested awards and holding lines for Craig Arnold

0shares vested or exercised

0gifted (net of own trusts)

−207withheld by the company for taxes

none reportedunvested awards, start → end

Includes unvested RSUs, amount not disclosed.

Held through	Share class	Oct 8, 2025	Oct 8, 2026
Direct includes unvested RSUs, amount not disclosed	Ordinary Shares	40,216	42,185

Reconciliation: minor difference of 65 shares. Difference is stated in footnotes (unreported vesting, exempt acquisition or transfer).

Thierry Pieton

Minor difference of 1,126 shares. Difference is stated in footnotes (unreported vesting, exempt acquisition or transfer). Includes unvested RSUs, amount not disclosed.

EVP & Chief Financial Officer

40K

50K

no sales

Vesting, gifts, unvested awards and holding lines for Thierry Pieton

0shares vested or exercised

0gifted (net of own trusts)

−3Kwithheld by the company for taxes

32K → 61Kunvested awards, start → end

Includes unvested RSUs, amount not disclosed.

Held through	Share class	Oct 8, 2025	Oct 8, 2026
Direct includes unvested RSUs, amount not disclosed	Ordinary Shares	39,958	49,645

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
29,574	$94.30	Mar 3, 2035	$0
61,338	$91.97	Jul 28, 2035	$103K
81,945	$86.68	Aug 3, 2036	$571K

Estimate: options held × ($93.65 − strike price), using the most recent insider trade price on Form 4 (Sep 16, 2026), not a market close.

Reconciliation: minor difference of 1,126 shares. Difference is stated in footnotes (unreported vesting, exempt acquisition or transfer).

Harry Kiil

Minor difference of 1,059 shares. Difference is stated in footnotes (unreported vesting, exempt acquisition or transfer). Includes unvested RSUs, amount not disclosed.

EVP & President Cardiovascular

36K

−58K

42K

not meaningful

Vesting, gifts, unvested awards and holding lines for Harry Kiil

+66Kshares vested or exercised

0gifted (net of own trusts)

−12Kwithheld by the company for taxes

68K → 76Kunvested awards, start → end

Includes unvested RSUs, amount not disclosed.

Held through	Share class	Oct 8, 2025	Oct 8, 2026
Direct includes unvested RSUs, amount not disclosed	Ordinary Shares	35,615	42,186

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
34,934	$112.43	Dec 10, 2031	$0
11,606	$93.08	Aug 1, 2032	$7K
18,926	$87.76	Jul 31, 2033	$111K
1,155	$80.00	Jul 29, 2034	$16K
53,671	$91.97	Jul 28, 2035	$90K
65,556	$86.68	Aug 3, 2036	$457K

Estimate: options held × ($93.65 − strike price), using the most recent insider trade price on Form 4 (Sep 16, 2026), not a market close.

Reconciliation: minor difference of 1,059 shares. Difference is stated in footnotes (unreported vesting, exempt acquisition or transfer).

Matthew Walter

Minor difference of 805 shares. Difference is stated in footnotes (unreported vesting, exempt acquisition or transfer). Includes unvested RSUs, amount not disclosed.

SVP, Chief HR Officer

32K

−3.1K

40K

+25%

Vesting, gifts, unvested awards and holding lines for Matthew Walter

+9.1Kshares vested or exercised

0gifted (net of own trusts)

−4.5Kwithheld by the company for taxes

42K → 48Kunvested awards, start → end

Includes unvested RSUs, amount not disclosed.

Held through	Share class	Oct 8, 2025	Oct 8, 2026
Direct includes unvested RSUs, amount not disclosed	Ordinary Shares	31,857	39,928

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
1,283	$78.00	Aug 3, 2025	$20K
1,704	$88.06	Aug 1, 2026	$10K
1,787	$83.97	Jul 31, 2027	$17K
2,542	$89.08	Jul 30, 2028	$12K
191	$89.45	Oct 29, 2028	$802
5,330	$103.26	Jul 29, 2029	$0
7,652	$97.33	Aug 3, 2030	$0
6,944	$131.26	Aug 2, 2031	$0
9,908	$93.08	Aug 1, 2031	$6K
24,525	$87.76	Jul 31, 2033	$144K
56,364	$80.00	Jul 29, 2034	$769K
30,669	$91.97	Jul 28, 2035	$52K
40,973	$86.68	Aug 3, 2036	$286K

Estimate: options held × ($93.65 − strike price), using the most recent insider trade price on Form 4 (Sep 16, 2026), not a market close.

Reconciliation: minor difference of 805 shares. Difference is stated in footnotes (unreported vesting, exempt acquisition or transfer).

Michelle Quinn

Minor difference of 697 shares. Difference is stated in footnotes (unreported vesting, exempt acquisition or transfer). Includes unvested RSUs, amount not disclosed.

EVP, GC and Secretary

22K

27K

no sales

Vesting, gifts, unvested awards and holding lines for Michelle Quinn

0shares vested or exercised

0gifted (net of own trusts)

−2.1Kwithheld by the company for taxes

14K → 29Kunvested awards, start → end

Includes unvested RSUs, amount not disclosed.

Held through	Share class	Oct 8, 2025	Oct 8, 2026
Direct includes unvested RSUs, amount not disclosed	Ordinary Shares	21,747	26,721

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
38,336	$91.97	Jul 28, 2035	$64K
45,070	$86.68	Aug 3, 2036	$314K

Estimate: options held × ($93.65 − strike price), using the most recent insider trade price on Form 4 (Sep 16, 2026), not a market close.

Reconciliation: minor difference of 697 shares. Difference is stated in footnotes (unreported vesting, exempt acquisition or transfer).

Kweli Thompson

Minor difference of 188 shares. Difference is stated in footnotes (unreported vesting, exempt acquisition or transfer). Includes unvested RSUs, amount not disclosed. Unvested RSUs stated in footnotes are excluded from owned shares. Started reporting during the period; starting holdings are from the Form 3.

EVP & President, Neuroscience

22K

35K

no sales

Vesting, gifts, unvested awards and holding lines for Kweli Thompson

0shares vested or exercised

0gifted (net of own trusts)

−1.7Kwithheld by the company for taxes

22K → 40Kunvested awards, start → end

Includes unvested RSUs, amount not disclosed.
Unvested RSUs stated in footnotes are excluded from owned shares.
Started reporting during the period; starting holdings are from the Form 3.

Held through	Share class	Oct 8, 2025	Oct 8, 2026
Direct includes unvested RSUs, amount not disclosed	Ordinary Shares	21,647	35,390

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
1,704	$88.06	Aug 1, 2026	$10K
1,608	$74.67	Jan 30, 2027	$31K
4,407	$83.97	Jul 31, 2027	$43K
6,271	$89.08	Jul 30, 2028	$29K
1,615	$103.26	Jul 29, 2029	$0
10,181	$97.33	Aug 3, 2030	$0
6,358	$131.26	Aug 2, 2031	$0
26,890	$93.08	Aug 1, 2032	$15K
25,408	$87.76	Jul 31, 2033	$150K
1,540	$80.00	Jul 29, 2034	$21K
22,363	$91.97	Jul 28, 2035	$38K
49,167	$86.68	Aug 3, 2036	$343K

Estimate: options held × ($93.65 − strike price), using the most recent insider trade price on Form 4 (Sep 16, 2026), not a market close.

Reconciliation: minor difference of 188 shares. Difference is stated in footnotes (unreported vesting, exempt acquisition or transfer).

Scott Donnelly

Minor difference of 145 shares. Difference is stated in footnotes (unreported vesting, exempt acquisition or transfer). Includes unvested RSUs, amount not disclosed. Additional holdings last reported more than 3 years ago are shown separately and excluded from totals.

Director

22K

24K

no sales

Vesting, gifts, unvested awards and holding lines for Scott Donnelly

0shares vested or exercised

0gifted (net of own trusts)

−207withheld by the company for taxes

none reportedunvested awards, start → end

Includes unvested RSUs, amount not disclosed.
Additional holdings last reported more than 3 years ago are shown separately and excluded from totals.

Held through	Share class	Oct 8, 2025	Oct 8, 2026
Direct includes unvested RSUs, amount not disclosed	Ordinary Shares	21,630	23,679

Additional holdings last reported May 3, 2022, not confirmed since: 245 shares. Not included in any total or percentage on this page.

Spouse Trust, Ordinary Shares: 245 shares, last reported May 3, 2022

Reconciliation: minor difference of 145 shares. Difference is stated in footnotes (unreported vesting, exempt acquisition or transfer).

Elizabeth Nabel

Minor difference of 65 shares. Difference is stated in footnotes (unreported vesting, exempt acquisition or transfer). Includes unvested RSUs, amount not disclosed.

Director

18K

20K

no sales

Vesting, gifts, unvested awards and holding lines for Elizabeth Nabel

0shares vested or exercised

0gifted (net of own trusts)

−207withheld by the company for taxes

none reportedunvested awards, start → end

Includes unvested RSUs, amount not disclosed.

Held through	Share class	Oct 8, 2025	Oct 8, 2026
Direct includes unvested RSUs, amount not disclosed	Ordinary Shares	17,615	19,584

Reconciliation: minor difference of 65 shares. Difference is stated in footnotes (unreported vesting, exempt acquisition or transfer).

Denise Blomquist

Minor difference of 438 shares. Difference is stated in footnotes (unreported vesting, exempt acquisition or transfer). Includes unvested RSUs, amount not disclosed.

Chief Accounting Officer

12K

16K

no sales

Vesting, gifts, unvested awards and holding lines for Denise Blomquist

+1.7Kshares vested or exercised

−1.1Kgifted (net of own trusts)

−915withheld by the company for taxes

6.9K → 7.6Kunvested awards, start → end

Includes unvested RSUs, amount not disclosed.

Held through	Share class	Oct 8, 2025	Oct 8, 2026
Direct includes unvested RSUs, amount not disclosed	Ordinary Shares	12,428	16,398

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
351	$88.06	Aug 1, 2026	$2K
1,102	$83.97	Jul 31, 2027	$11K
523	$89.08	Jul 30, 2028	$2K
2,762	$89.45	Oct 29, 2028	$12K
1,884	$103.26	Jul 29, 2029	$0
3,306	$97.33	Aug 3, 2030	$0
2,620	$131.26	Aug 2, 2031	$0
3,821	$93.08	Aug 1, 2032	$2K
769	$87.34	Oct 31, 2032	$5K
4,333	$87.76	Jul 31, 2033	$26K
1,278	$91.97	Jul 28, 2035	$2K
1,366	$86.68	Aug 3, 2036	$10K

Estimate: options held × ($93.65 − strike price), using the most recent insider trade price on Form 4 (Sep 16, 2026), not a market close.

Reconciliation: minor difference of 438 shares. Difference is stated in footnotes (unreported vesting, exempt acquisition or transfer).

Andrea Goldsmith

Includes unvested RSUs, amount not disclosed.

Director

10K

no sales

Vesting, gifts, unvested awards and holding lines for Andrea Goldsmith

0shares vested or exercised

0gifted (net of own trusts)

none reportedunvested awards, start → end

Includes unvested RSUs, amount not disclosed.

Held through	Share class	Oct 8, 2025	Oct 8, 2026
Direct includes unvested RSUs, amount not disclosed	Ordinary Shares	10,247	10,247

Kevin Lofton

Minor difference of 65 shares. Difference is stated in footnotes (unreported vesting, exempt acquisition or transfer). Includes unvested RSUs, amount not disclosed.

Director

8.2K

10K

no sales

Vesting, gifts, unvested awards and holding lines for Kevin Lofton

0shares vested or exercised

0gifted (net of own trusts)

−207withheld by the company for taxes

none reportedunvested awards, start → end

Includes unvested RSUs, amount not disclosed.

Held through	Share class	Oct 8, 2025	Oct 8, 2026
Direct includes unvested RSUs, amount not disclosed	Ordinary Shares	8,171	10,140

Reconciliation: minor difference of 65 shares. Difference is stated in footnotes (unreported vesting, exempt acquisition or transfer).

Lidia Fonseca

Minor difference of 65 shares. Difference is stated in footnotes (unreported vesting, exempt acquisition or transfer). Includes unvested RSUs, amount not disclosed.

Director

5.7K

7.6K

no sales

Vesting, gifts, unvested awards and holding lines for Lidia Fonseca

0shares vested or exercised

0gifted (net of own trusts)

−207withheld by the company for taxes

none reportedunvested awards, start → end

Includes unvested RSUs, amount not disclosed.

Held through	Share class	Oct 8, 2025	Oct 8, 2026
Direct includes unvested RSUs, amount not disclosed	Ordinary Shares	5,675	7,644

Reconciliation: minor difference of 65 shares. Difference is stated in footnotes (unreported vesting, exempt acquisition or transfer).

William Jellison

Includes unvested RSUs, amount not disclosed.

Director

6.4K

no sales

Vesting, gifts, unvested awards and holding lines for William Jellison

0shares vested or exercised

0gifted (net of own trusts)

none reportedunvested awards, start → end

Includes unvested RSUs, amount not disclosed.

Held through	Share class	Oct 8, 2025	Oct 8, 2026
Direct includes unvested RSUs, amount not disclosed	Ordinary Shares	5,000	6,444

Gregory Lewis

Minor difference of 65 shares. Difference is stated in footnotes (unreported vesting, exempt acquisition or transfer). Includes unvested RSUs, amount not disclosed.

Director

3.8K

5.8K

no sales

Vesting, gifts, unvested awards and holding lines for Gregory Lewis

0shares vested or exercised

0gifted (net of own trusts)

−207withheld by the company for taxes

none reportedunvested awards, start → end

Includes unvested RSUs, amount not disclosed.

Held through	Share class	Oct 8, 2025	Oct 8, 2026
Direct includes unvested RSUs, amount not disclosed	Ordinary Shares	3,785	5,754

Reconciliation: minor difference of 65 shares. Difference is stated in footnotes (unreported vesting, exempt acquisition or transfer).

Joon Lee

Includes unvested RSUs, amount not disclosed.

Director

1.8K

no sales

Vesting, gifts, unvested awards and holding lines for Joon Lee

0shares vested or exercised

0gifted (net of own trusts)

none reportedunvested awards, start → end

Includes unvested RSUs, amount not disclosed.

Held through	Share class	Oct 8, 2025	Oct 8, 2026
Direct includes unvested RSUs, amount not disclosed	Ordinary Shares	0	1,803

John Groetelaars

Includes unvested RSUs, amount not disclosed.

Director

1.4K

no sales

Vesting, gifts, unvested awards and holding lines for John Groetelaars

0shares vested or exercised

0gifted (net of own trusts)

none reportedunvested awards, start → end

Includes unvested RSUs, amount not disclosed.

Held through	Share class	Oct 8, 2025	Oct 8, 2026
Direct includes unvested RSUs, amount not disclosed	Ordinary Shares	0	1,444

22 of 22 insiders fully reconciled: starting holdings plus reported transactions match ending holdings (4 exactly, 18 with a minor or footnoted difference). Percentages cover 19 of 22 officers and directors. Left out: Harry Kiil (most of their shares vested during the period, so a percentage would mislead); Joon Lee and John Groetelaars (held no vested shares at the start). "Still held" compares ending with starting vested shares; a plus sign means the holding grew.

What explains the selling$8.9M of sales by plan status, purpose, seller and month

Officer and director open-market sales: $8.9M across 91,298 shares. Plan status and stated purpose are separate questions, and a sale can have both.

By plan status

Disclosed plan · $258K · 3%

97%

The lighter segment is sales with no plan disclosed in the filing ($8.7M), including tax-related sales outside a plan.

No plan disclosed · $8.7M

Sales with no 10b5-1 plan and no tax reference in the filing. $5.6M of it is Harry Kiil. No plan disclosed is a statement about the filing, not about why the sale happened. Largest such sale: Harry Kiil, Feb 19, 2026

Taxes

98,529 shares ($8.4M) were withheld by the company for taxes, which isn't a market sale.

Seller	Shares sold	Proceeds	Under a disclosed plan	Share of total	Sales dates
Harry Kiil EVP & President Cardiovascular	58K	$5.6M	0%	63%	Feb 19, 2026 to Sep 16, 2026
Gregory Smith EVP Global Ops & Supply Chain	30K	$3.1M	0%	34%	Nov 19, 2025 to Nov 19, 2025
Matthew Walter SVP, Chief HR Officer	3.1K	$258K	100%	3%	Jul 8, 2026 to Jul 8, 2026

Sales by month

Month	Sale proceeds	Disclosed plan	To cover taxes	No plan disclosed
Oct 2025	$0	$0	$0	$0
Nov 2025	$3.1M	$0	$0	$3.1M
Dec 2025	$0	$0	$0	$0
Jan 2026	$0	$0	$0	$0
Feb 2026	$5.1M	$0	$0	$5.1M
Mar 2026	$0	$0	$0	$0
Apr 2026	$0	$0	$0	$0
May 2026	$0	$0	$0	$0
Jun 2026	$337K	$0	$0	$337K
Jul 2026	$258K	$258K	$0	$0
Aug 2026	$0	$0	$0	$0
Sep 2026	$139K	$0	$0	$139K
Oct 2026	$0	$0	$0	$0

Is this normal? Selling year by year5 earlier years to compare with

In line with the past 5 years. 3 insiders sold; the average is 5 a year.

12 months ending	Shares sold	Insiders who sold	Proceeds
Oct 8, 2026 Latest 12 months	91K	3	$8.9M
Oct 8, 2025 1 year earlier	31K	2	$2.7M
Oct 8, 2024 2 years earlier	56K	4	$4.7M
Oct 9, 2023 3 years earlier	39K	5	$3.2M
Oct 9, 2022 4 years earlier	15K	3	$1.5M
Oct 9, 2021 5 years earlier	263K	9	$33.2M

Open-market sales (Form 4 code S) by people who were officers or directors, in split-adjusted shares. Earlier years include people who have since left. A sale that an outside holder also reports (a family trust, a fund) is counted with outside holders in every year. Shares, not dollars, are compared, so a change in the stock price doesn't look like a change in selling. Years the filings don't fully cover are shown but left out of the average.

Known gaps and uncertaintyEvery officer and director reconciles

Every officer and director reconciles for this period.

Geoffrey Martha: minor difference of 3,555 shares. Difference is stated in footnotes (unreported vesting, exempt acquisition or transfer).

Gregory Smith: minor difference of 59 shares. Difference is under 0.5% of holdings.

Brett Wall: minor difference of 778 shares. Difference is stated in footnotes (unreported vesting, exempt acquisition or transfer).

Michael Marinaro: minor difference of 1,578 shares. Difference is stated in footnotes (unreported vesting, exempt acquisition or transfer).

Kendall Powell: minor difference of 854 shares. Difference is stated in footnotes (unreported vesting, exempt acquisition or transfer).

Randall Hogan: minor difference of 65 shares. Difference is stated in footnotes (unreported vesting, exempt acquisition or transfer).

Craig Arnold: minor difference of 65 shares. Difference is stated in footnotes (unreported vesting, exempt acquisition or transfer).

Thierry Pieton: minor difference of 1,126 shares. Difference is stated in footnotes (unreported vesting, exempt acquisition or transfer).

Harry Kiil: minor difference of 1,059 shares. Difference is stated in footnotes (unreported vesting, exempt acquisition or transfer).

Matthew Walter: minor difference of 805 shares. Difference is stated in footnotes (unreported vesting, exempt acquisition or transfer).

Michelle Quinn: minor difference of 697 shares. Difference is stated in footnotes (unreported vesting, exempt acquisition or transfer).

Kweli Thompson: minor difference of 188 shares. Difference is stated in footnotes (unreported vesting, exempt acquisition or transfer).

Scott Donnelly: minor difference of 145 shares. Difference is stated in footnotes (unreported vesting, exempt acquisition or transfer).

Elizabeth Nabel: minor difference of 65 shares. Difference is stated in footnotes (unreported vesting, exempt acquisition or transfer).

Denise Blomquist: minor difference of 438 shares. Difference is stated in footnotes (unreported vesting, exempt acquisition or transfer).

Kevin Lofton: minor difference of 65 shares. Difference is stated in footnotes (unreported vesting, exempt acquisition or transfer).

Lidia Fonseca: minor difference of 65 shares. Difference is stated in footnotes (unreported vesting, exempt acquisition or transfer).

Gregory Lewis: minor difference of 65 shares. Difference is stated in footnotes (unreported vesting, exempt acquisition or transfer).

Inferred rename: "Spouse Rev Trust" is treated as the same holder as "Spouse Trust", because the old name was never reported again and the new one opened with the same balance (245 shares). Old name, new name

Inferred rename: "GRAT" is treated as the same holder as "2017 GRAT", because the old name was never reported again and the new one opened with the same balance (7,615 shares). Old name, new name

External context: we only cite outside events when a documented connection exists. None is shown for this period.

Sources and methodology737 filings from SEC EDGAR, and how we read them

All 737 Forms 3, 4 and 5 filed for Medtronic (SEC CIK 1613103) from Jan 28, 2015 to Sep 17, 2026, retrieved from SEC EDGAR on Oct 8, 2026. Prices are the ones reported in each filing, often weighted averages. 7 filings were left out because Medtronic filed them as an owner of another company's stock.

Holdings. Each holding line (a share class plus an owner, such as a trust or LLC) carries its last reported balance forward. Entities first reported during the period start at zero, so transfers between an insider's own trusts don't count as selling. Lines not reported for three years or more are listed separately and left out of totals.

Sales. A sale counts as under a 10b5-1 plan if its footnote cites one or the filing's Rule 10b5-1 box is checked, and as tax-related if its footnote cites tax obligations or sell-to-cover. Shares withheld by the company for taxes are listed separately. Sales with neither attribute are labeled "no plan disclosed".

Full methodology

Former or inactive filers (24)No filing in 18 months; last reported balances, not in any total

Name	Last filed	Last reported balance
Gary Corona	Jan 23, 2025	44,255 shares, last reported balance as of Jan 21, 2025
Sean Salmon	Dec 17, 2024	64,722 shares, last reported balance as of Dec 16, 2024
Ivan Fong	Dec 17, 2024	54,692 shares, last reported balance as of Dec 16, 2024
Jennifer Kirk	Dec 10, 2024	28,011 shares, last reported balance as of Dec 6, 2024
Karen Parkhill	Aug 6, 2024	99,118 shares, last reported balance as of Aug 2, 2024
Denise Oleary	May 3, 2024	77,057 shares, last reported balance as of May 1, 2024
Robert White	Dec 12, 2023	49,910 shares, last reported balance as of Dec 8, 2023
Hoedt Ten	Aug 7, 2023	52,748 shares, last reported balance as of Aug 3, 2023
Richard Anderson	May 3, 2023	120,328 shares, last reported balance as of May 2, 2023
Carol Surface	Aug 3, 2022	26,769 shares, last reported balance as of Aug 1, 2022
John Liddicoat	Aug 2, 2022	37,374 shares, last reported balance as of Jul 29, 2022
Richard Kuntz	Nov 9, 2021	74,945 shares, last reported balance as of Nov 5, 2021
Bradley Lerman	Nov 9, 2021	48,635 shares, last reported balance as of Nov 5, 2021
James Lenehan	May 4, 2021	57,849 shares, last reported balance as of May 3, 2021
Michael Leavitt	May 4, 2021	21,779 shares, last reported balance as of May 3, 2021
Omar Ishrak	Dec 11, 2020	617,287 shares, last reported balance as of Oct 15, 2020
Michael Coyle	Nov 5, 2020	194,744 shares, last reported balance as of Nov 3, 2020
Hooman Hakami	Sep 12, 2019	30,761 shares, last reported balance as of Sep 10, 2019
Robert Pozen	Aug 24, 2018	60,964 shares, last reported balance as of Aug 23, 2018
Shirley Jackson	May 2, 2018	38,525 shares, last reported balance as of May 1, 2018
Bryan Hanson	Dec 18, 2017	88,818 shares, last reported balance as of Dec 15, 2017
Gary Ellis	Jan 4, 2017	193,957 shares, last reported balance as of Dec 30, 2016
Preetha Reddy	May 4, 2016	7,823 shares, last reported balance as of May 2, 2016
Christopher OConnell	Feb 20, 2015	95,928 shares, last reported balance as of Feb 19, 2015

Medtronic insiders sold $8.9M in the past 12 months. How much of their stake is that?

What stands out

Who sold, and how much of their stake

Selling by month

Common questions

Is the Medtronic CEO selling stock?

Why are Medtronic insiders selling?

Are any Medtronic insiders buying?

How much of their stake did Medtronic insiders sell?

The evidence

No plan disclosed · $8.7M

Taxes

Sales by month